Tetrabenazine – 250 mg

Brand:
Cayman
CAS:
58-46-8
Storage:
-20
UN-No:
Non-Hazardous - /

Tetrabenazine is an inhibitor of vesicular monoamine transporter 2 (VMAT2) that is selective over VMAT1 (Kis = 97 and >20,000 nM, respectively, in a serotonin uptake assay).{26973} It dose-dependently reduces levels of the monoamines norepinephrine (Item No. 16673), dopamine (Item No. 21992), and serotonin (5-HT; Item No. 14332) in rat brain and has been used to induce depressive-like behavior in animal models.{47227,47228} Tetrabenazine (5 mg/kg) improves performance in balance beam and rotarod tests and prevents decreases in the number of striatal medium spiny neurons (MSNs) in a YAC128 transgenic mouse model of Huntington’s disease.{47229} Formulations containing tetrabenazine have been used in the treatment of chorea associated with Huntington’s disease.  

 

Available on backorder

SKU: 20380 - Category:

Description

An inhibitor of VMAT2 that is selective over VMAT1 (Kis = 97 and >20,000 nM, respectively, in a serotonin uptake assay); dose-dependently reduces levels of the monoamines norepinephrine, dopamine, and 5-HT in rat brain; has been used to induce depressive-like behavior in animal models; improves performance in balance beam and rotarod tests and prevents decreases in the number of striatal MSNs in a YAC128 transgenic mouse model of Huntington’s disease at 5 mg/kg


Formal name: rel-1,3R,4,6,7,11bR-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-one

Synonyms:  NSC 169886|NSC 172187|Ro 1-9569|TBZ

Molecular weight: 317.4

CAS: 58-46-8

Purity: ≥98% (mixture of enantiomers)

Formulation: A crystalline solid


Product Type|Biochemicals|Transporter & Exchanger Modulators||Research Area|Neuroscience|Behavioral Neuroscience|Depression||Research Area|Neuroscience|Neurodegenerative Disorders|Huntington’s Disease||Research Area|Neuroscience|Neuroprotection